Search is Powered by Google
Cancer / Oncology News

Cancer Molecular Diagnostics: On The Critical Path To Personalized Medicine

Main Category: Cancer / Oncology
Article Date: 23 Jul 2008 - 2:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

The Healthcare practice at Frost & Sullivan is pleased to announce its 2008 Quarterly Analyst Briefing Presentation on the North American cancer molecular diagnostics market to be held on Thursday July 24, 2008 at 10:00 a.m. PDT.

The presentation will cover strategic insight into the U.S. cancer molecular diagnostics market and how the market correlates with growth in the world of personalized medicine. The briefing will examine the competitive dynamics of two main routes to get cancer molecular diagnostic tests to market - CLIA versus IVD models. It is crucial for any company or investor to examine the details of the rapid growth taking place in the fragmented space of the cancer molecular diagnostics market in order to exploit growth opportunities.

The briefing will benefit: clinical diagnostics companies and pharmaceutical companies, biotechnology companies, personalized medicine companies, companion diagnostics companies, investors and venture capital firms, life sciences research tools providers, platform technology providers, biomarker discovery companies, pharmacogenomics services providers, and contract research organizations. The briefing will highlight the critical questions that surround companion diagnostics and pharmacogenomicsyea.

"The regulatory environment around the cancer molecular diagnostics is still in flux," states Frost & Sullivan Senior Research Analyst Sudeep Basu, PhD. "While the near term benefit the adoption of a CLIA lab-based strategy are reaping, the long term view must be kept in perspective."

To participate, please email Stephanie Ochoa, Corporate Communications, at stephanie.ochoa@frost.com with the following information: your full name, title, company name, company telephone number, company e-mail address, city, state and country. Upon receipt of the above information, a registration link will be emailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit www.frost.com.




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...